AI Generated Image
Trump low-cost GLP-1 plan a likely boost for Eli Lilly, Novo Nordisk
statnews.com • • business
Key Points:
- The Trump administration negotiated a deal with drugmakers Eli Lilly and Novo Nordisk to set a $245 monthly price for GLP-1 drugs in Medicare and Medicaid, aiming to lower prices in exchange for higher sales volume.
- The agreed price was intended to apply to all GLP-1 drugs, including those for obesity, which had not previously been covered by Medicare.
- The lower price was contingent on private Medicare insurers agreeing to cover GLP-1 drugs for all uses with a $50 copay, a condition not publicly disclosed by the administration.
- Despite the deal, drug companies managed to increase sales volume without consistently lowering prices as initially expected.
